Tests PF-08049820 tablets in adults with moderate to severe eczema
Tests a daily tablet against placebo in adults with moderate to severe eczema.
Plain-language title generated from the registry record
Registry title: A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
Key facts
- Where
- Huntington Beach, Lorain, Los Angeles, Margate, Mayfield Heights, Miami, Northridge, Philadelphia, Phoenix, Pittsburgh, Santa Monica, Scottsdale, and The Bronx, United StatesSee the 18 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Source: NCT07216027, who can take part
Where in United States
- Marvel Clinical ResearchHuntington Beach, United StatesTaking people
- Apex Clinical Research Center, LLC. - LorainLorain, United StatesTaking people
- Metropolis Dermatology - DTLALos Angeles, United StatesNot yet recruiting
- Gsi Clinical ResearchMargate, United StatesTaking people
- Apex Clinical Research Center, LLCMayfield Heights, United StatesTaking people
- Skin Research of South FloridaMiami, United StatesNo longer taking part
- Northridge Clinical TrialsNorthridge, United StatesTaking people
- Paddington Testing Co IncPhiladelphia, United StatesTaking people
- Mayo Clinic HospitalPhoenix, United StatesTaking people
- Mayo Clinic Specialty BuildingPhoenix, United StatesTaking people
- UPMC Department of DermatologyPittsburgh, United StatesTaking people
- Clinical Science InstituteSanta Monica, United StatesTaking people
- Mayo ClinicScottsdale, United StatesTaking people
- Montefiore - Clinical Research CenterThe Bronx, United StatesTaking people
- Montefiore - Greene Medical Arts PavillionThe Bronx, United StatesTaking people
- Montefiore - Jacobi Dermatology ClinicThe Bronx, United StatesTaking people
- Montefiore - The Dermatology CenterThe Bronx, United StatesTaking people
- Montefiore Medical CenterThe Bronx, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pfizer
- Trial code
- NCT07216027EU 2025-522965-31-00
- Record updated
- 5 November 2026
- Original description
The purpose of this study is to learn if the study medicine (PF-08049820) is safe and effective for the treatment of atopic dermatitis (AD), also known as eczema, or atopic eczema. People with this condition may have severe itching and rashes on the skin.Read full original descriptionShow less
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08049820 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
The purpose of this study is to learn if the study medicine (PF-08049820) is safe and effective for the treatment of atopic dermatitis (AD), also known as eczema, or atopic eczema. People with this condition may have severe itching and rashes on the skin.
The study is seeking participants who:
1. Are 18 to 64 years of age; 2. Were confirmed to have AD at least 6 months ago; 3. Do not have a suitable prescribed medicine for AD; 4. Are considered by their doctors to have moderate to severe AD.
The study has two stages (Stage 1 and Stage 2). In both stages, eligible participants will take either PF-08049820 or placebo as tablets by mouth daily for 12 weeks. A placebo does not have any medicine in it but looks just like the medicine being studied. Participants will visit the clinic on Day 1, Weeks 1, 2, 4, 6, 8 and 12. They will have a follow-up visit at Week 16. During this time, the participant's health and skin condition will be checked. They will have blood and urine tests. They will also have to answer questions about their health, skin condition, and how much their skin condition affects their lives. The experiences of participants receiving the study medicine will be compared to those receiving placebo. This will help to understand if PF-08049820 is safe and effective.
Inclusion: Participants must meet the following criteria:; Are 18 to 64 years of age; Have clinical diagnosis of AD for at least 6 months prior to Day 1 and have diagnosis of AD confirmed by photographs; Have moderate to severe AD as defined by the following at screening and baseline visits:; Affected body surface area (BSA) greater than or equal to 10% and up to 60%; Validated Investigator's Global Assessment (vIGA) greater than or equal to 3; Eczema Area and Severity Index (EASI) greater than or equal to 16; AND; -Peak Pruritis Numeric Rating Scale (PP-NRS) greater than or equal to 4 at screening and a weekly average of greater than or equal to 4 at baseline visit; Do not have a suitable prescribed medicine for AD; Body Mass Index (BMI) of 18 to 38 kg/m2 and a total body weight greater than 48 kg (106 lbs).
Exclusion: Have an infection that requires treatment; Have other skin conditions other than AD; Participants must not meet the following criteria:; Have severe uncontrolled asthma; Regular use (more than 2 visits per week) of a tanning booth or phototherapy for AD within 4 weeks of the screening visit.